Cargando…

The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial

BACKGROUND: Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test for lifetime risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fredsøe, Jacob, Koetsenruyter, Jan, Vedsted, Peter, Kirkegaard, Pia, Væth, Michael, Edwards, Adrian, Ørntoft, Torben F., Sørensen, Karina D., Bro, Flemming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006905/ https://www.ncbi.nlm.nih.gov/pubmed/32032355 http://dx.doi.org/10.1371/journal.pmed.1003033

Ejemplares similares

A genetic risk assessment for prostate cancer influences patients’ risk perception and use of repeat PSA testing: a cross-sectional study in Danish general practice
por: Fredsøe, Jacob, et al.
Publicado: (2020)

A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice—the ProCaRis study: study protocol
por: Kirkegaard, Pia, et al.
Publicado: (2013)

Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study
por: Kirkegaard, Pia, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach
por: Risør, Bettina Wulff, et al.
Publicado: (2022)

A geographical cluster randomised stepped wedge study of continuing medical education and cancer diagnosis in general practice
por: Toftegaard, Berit Skjødeberg, et al.
Publicado: (2014)

Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer
por: Bjerre, Marianne T., et al.
Publicado: (2019)

Prognostic DNA Methylation Markers for Prostate Cancer
por: Strand, Siri H., et al.
Publicado: (2014)

Direct notification of cervical cytology results to women improves follow-up in cervical cancer screening - A cluster-randomised trial
por: Kristiansen, Bettina Kjær, et al.
Publicado: (2018)

Implementation of immunochemical faecal occult blood test in general practice: a study protocol using a cluster-randomised stepped-wedge design
por: Juul, Jakob Søgaard, et al.
Publicado: (2016)

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Thorn, Joanna C., et al.
Publicado: (2023)

Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling
por: Salachan, Paul Vinu, et al.
Publicado: (2022)

Use of hyperlinks in electronic test result communication: a survey study in general practice
por: Mukai, Thomas Ostersen, et al.
Publicado: (2012)

PSA testing for prostate cancer: an online survey of the views and reported practice of General Practitioners in the UK
por: Brett, Jo, et al.
Publicado: (2005)

Genetically adjusted PSA levels for prostate cancer screening
por: Kachuri, Linda, et al.
Publicado: (2023)

Association of GPs’ risk attitudes, level of empathy, and burnout status with PSA testing in primary care
por: Pedersen, Anette F, et al.
Publicado: (2015)

Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients
por: Schmidt, L, et al.
Publicado: (2018)

Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)
por: Turner, E L, et al.
Publicado: (2014)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Mental well-being and job satisfaction among general practitioners: a nationwide cross-sectional survey in Denmark
por: Nørøxe, Karen Busk, et al.
Publicado: (2018)

Impact of a continuing medical education meeting on the use and timing of urgent cancer referrals among general practitioners - a before-after study
por: Toftegaard, Berit Skjødeberg, et al.
Publicado: (2017)

Impact of continuing medical education in cancer diagnosis on GP knowledge, attitude and readiness to investigate – a before-after study
por: Toftegaard, Berit Skjødeberg, et al.
Publicado: (2016)

High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer
por: Ku, Anson, et al.
Publicado: (2021)

High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy
por: Mortensen, Martin Mørck, et al.
Publicado: (2014)

Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential
por: Fredsøe, Jacob, et al.
Publicado: (2020)

Supporting Informed Decision Making for Prostate Specific Antigen (PSA) Testing on the Web: An Online Randomized Controlled Trial
por: Evans, Rhodri, et al.
Publicado: (2010)

Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine
por: Fredsøe, Jacob, et al.
Publicado: (2022)

Patient delay in cancer studies: a discussion of methods and measures
por: Andersen, Rikke Sand, et al.
Publicado: (2009)

Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy
por: Mortensen, Martin Mørck, et al.
Publicado: (2015)

The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer–a cross-sectional study of patient characteristics and cancer probability
por: Ingeman, Mads Lind, et al.
Publicado: (2015)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline
por: Tikkinen, Kari A O, et al.
Publicado: (2018)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Association of Polymorphisms in the Prostate-Specific Antigen (PSA) Gene Promoter with Serum PSA Level and PSA Changes after Dutasteride Treatment in Korean Men with Benign Prostatic Hypertrophy
por: Park, Sung Woon, et al.
Publicado: (2010)

Mental well-being and job satisfaction in general practitioners in Denmark and their patients’ change of general practitioner: a cohort study combining survey data and register data
por: Nørøxe, Karen Busk, et al.
Publicado: (2019)

Danish Prostate Cancer Consortium Study 1 (DPCC-1) protocol: Multicentre prospective validation of the urine-based three-microRNA biomarker model uCaP
por: Fredsøe, Jacob, et al.
Publicado: (2023)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v539oad02o03i8hfqgh67u1d4g